Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Hepion Pharmaceuticals Inc (HEPA)

Hepion Pharmaceuticals Inc (HEPA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd. GlobeNewswire - Wed Dec 11, 7:00AM CST

HEPA : 0.4900 (-7.37%)
Hepion Pharmaceuticals Urges Shareholders to Approve Merger with Pharma Two B to Enhance Investment Potential Quiver Quantitative, Inc. - Mon Dec 2, 5:20PM CST

Hepion Pharmaceuticals urges shareholders to support its merger with Pharma Two B to enhance investment potential and address financial challenges.Quiver AI SummaryHepion Pharmaceuticals is urging its...

HEPA : 0.4900 (-7.37%)
Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B GlobeNewswire - Mon Dec 2, 7:00AM CST

HEPA : 0.4900 (-7.37%)
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger GlobeNewswire - Mon Nov 11, 7:00AM CST

HEPA : 0.4900 (-7.37%)
Hepion Pharmaceuticals (NASDAQ: HEPA) Reports Promising Phase 2 Trial Results for NASH Treatment Spotlight Growth - Mon May 22, 2023

Renocofilstat's Positive Outcomes Reinforce Antifibrotic Action Hepion Pharmaceuticals, a clinical stage biopharmaceutical company focusing on AI-assisted therapeutic drug development, recently

HEPA : 0.4900 (-7.37%)
Wall Street - shutterstock_93231562
Pre-Market Brief: Stocks Mostly Higher As Investors Await U.S. Inflation Data Barchart - Wed Jan 11, 2023

March S&P 500 futures (ESH23) are trending up +0.32% this morning after three major U.S. benchmark indices finished the regular session higher as market participants awaited U.S. inflation data for further...

ESH23 : 3,957.05s (-0.09%)
JD-.LN : 95.450 (-1.70%)
HEPA : 0.4900 (-7.37%)
BWEN : 1.8500 (+3.35%)
PROK : 1.5100 (+3.42%)
CONN : 0.0975 (-46.40%)
SHC : 13.24 (-0.23%)
STM : 24.61 (+0.53%)
Hepion Pharmaceuticals Announces Further Adjournment of Annual Meeting of Stockholders Globe Newswire - Fri Jul 22, 2022

EDISON, N.J., July 22, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on...

HEPA : 0.4900 (-7.37%)
Hepion Pharmaceuticals Further Strengthens Board with Appointments of Accomplished Biopharmaceutical Executives, Mr. Anand Reddi and Dr. Kaouthar Lbiati Globe Newswire - Tue Jun 28, 2022

EDISON, N.J., June 28, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on...

HEPA : 0.4900 (-7.37%)
Hepion Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders Globe Newswire - Fri Jun 24, 2022

EDISON, N.J., June 24, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on...

HEPA : 0.4900 (-7.37%)
Hepion Pharmaceuticals Receives FDA Orphan Drug Status Designation for Rencofilstat for the Treatment of Hepatocellular Carcinoma Globe Newswire - Mon Jun 20, 2022

EDISON, N.J., June 20, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on...

HEPA : 0.4900 (-7.37%)

Barchart Exclusives

Oracle Stock Is Off Its Highs and Could Be Cheap Here Barchart - 59 minutes ago
Oracle Corp. produced higher revenue in Q2 but lower free cash flow and FCF margins. However, ORCL stock is now off its highs and could be undervalued here. Shorting out-of-the-money puts is one way to play it. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot